Has Jill Conway, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,005,030 in general payments to Jill Conway, MD across 911 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jill Conway, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jill Conway, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jill Conway, MD

Neurology · Charlotte, NCNPI 1205991502

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $721,267 of the $1,005,030 with a category attached, or 71.8%. 16 manufacturers reported payments, led by Sanofi at 24.7% of the total. Reporting peaked in 2019 at $384,589 and has fallen 73.5% since, to $101,818 in 2025. Among neurology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,005,030in general payments, 2019–2025

Across 911 payments — averaging $1103.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi$248K
AstraZeneca$242K
Genentech USA, Inc.$157K
EMD Serono, Inc.$143K
Amgen$88K
Novartis$86K
plus $41K from 10 others

$571,156in research payments, 2019–2025

Across 40 payments — averaging $14,279 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novartis$331K
F. Hoffmann-la Roche AG$172K
Roche Products Limited$50K
Adamas Pharmaceuticals, Inc.$14K
Sanofi$3K
EMD Serono, Inc.$522

What the payments were for

Consulting fees$178,18618%
Speaking & faculty fees$721,26772%
Travel & lodging$84,9948%
Food & beverage$17,6402%
Education$2100%
Gifts$2,7330%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi	230	$248,409
AstraZeneca	217	$242,102
Genentech USA, Inc.	117	$156,642
EMD Serono, Inc.	126	$142,544
Amgen(2 entities)	76	$88,460
Novartis	91	$85,549
Bristol Myers Squibb	24	$16,204
TG Therapeutics, Inc.	12	$9,010
E.r. Squibb & Sons, L.L.C.	6	$7,760
Greenwich Biosciences, Inc.	1	$3,570
Biogen	2	$2,316
Johnson & Johnson	1	$1,320
Bayer	3	$849
Sanofi-aventis U.S. LLC	2	$124
AbbVie	1	$92
Genentech, Inc.	2	$80

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

AUBAGIO$165,223
OCREVUS$138,957
Mavenclad$102,735
UPLIZNA$73,270
SOLIRIS$66,981
ULTOMIRIS$57,865
MAYZENT$36,957
LEMTRADA$33,302
ZEPOSIA$19,349
Rebif$11,423
DISEASE STATE$10,749
GILENYA$8,112
KESIMPTA$6,977
TYSABRI$2,260
TECFIDERA$2,260
AVONEX$2,260
PLEGRIDY$2,260
BRIUMVI$1,807
Betaseron$780
Ocrevus Zunovo$113

How this compares

$1,005,030 in reported general payments places this provider in the 95th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina →

Medicare billing

Part B allowed, 2024

$22,369

Medicare patients

106

Services billed

324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Kesimpta PenOfatumumab	67	$570,147
Glatiramer Acetate	17	$44,768
Dimethyl Fumarate	20	$27,174
Dalfampridine ErDalfampridine	38	$7,501
Gabapentin	124	$2,647
Baclofen	135	$2,637
FingolimodFingolimod Hcl	11	$2,318
Teriflunomide	35	$1,529
Modafinil	21	$1,137
Tizanidine Hcl	24	$802
Solifenacin Succinate	12	$604
Duloxetine Hcl	23	$454
Pregabalin	18	$415
Oxybutynin Chloride ErOxybutynin Chloride	13	$254
Sertraline Hcl	17	$145

Paid to pharmacies, not to this prescriber.

Other neurology in Charlotte

Matthew CarraroCharlotte$695K
Megan DonnellyCharlotte$601K
Sanjay IyerCharlotte$581K
Urvi DesaiCharlotte$262K
Danielle Englert DoggettCharlotte$215K
Robert WigginsCharlotte$138K
Ardith CourtneyCharlotte$120K
Joseph ChipmanCharlotte$118K
Kurt WashburnCharlotte$66K
Ziad HageCharlotte$58K

See the full list for North Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →